Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.